The Institute for Hepatitis and Virus Research (IHVR) is using pharmaceutical
grade high-throughput robotic systems to screen its own compound library
of more than 80,000 carefully selected diverse molecules for therapeutic
activity against hepatitis B, hepatitis C, and other clinical targets
that fall out of the mainstream of pharmaceutical interest, but are important
health matters, nonetheless. The anti-hepatitis virus imino-sugar structure
activity relationship derivative program will be continued.
The theory regarding hepatitis virus persistence and evasion of proteasomal
degradation will be explored. The theory regarding the role of host defense
pathways in the augmentation of hepatitis B resistance to antivirals will
also be explored.